- Home
- LPTX
as 10-29-2025 9:37am EST
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 35.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 7.8M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $4.79 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Leap Therapeutics Inc. News
LPTX Breaking Stock News: Dive into LPTX Ticker-Specific Updates for Smart Investing
PR Newswire
20 days ago
Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
CoinDesk
23 days ago
Leap Therapeutics Shares Jump on $59M Winklevoss-Led Crypto Deal
Associated Press Finance
23 days ago
BC-Most Active Stocks
PR Newswire
23 days ago
Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
MT Newswires
4 months ago
Leap Therapeutics' Colorectal Cancer Study Shows Significant Benefits; Workforce Cuts Coming
PR Newswire
4 months ago
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
PR Newswire
6 months ago
Leap Therapeutics Reports First Quarter 2025 Financial Results
PR Newswire
6 months ago
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
Compare LPTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LPTX Leap Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.